Emma Hansson, Ph.D.

Deputy Quality Assurance Officer, Senior Consultant

Portrait-of-Emma-Hansson_Pharmetheus

Bio

  • Joined Pharmetheus in 2016, serving as Quality Assurance Officer, leading continuous improvement of internal processes, actively working in client projects, and developing the regulatory strategy 
  • Expertise includes regulatory advice, pediatrics, and clinical pharmacology, in therapeutic areas such as oncology, endocrinology, and infectious diseases as well as quality assurance
  • Previously worked as Pharmacokinetics and Pharmacometrics Assessor at the Medical Products Agency, Sweden, where she made scientific assessments of marketing authorization applications with a focus on clinical pharmacology and pharmacometrics analyses, and QA Manager at LINK Medical, Sweden
  • M.Sc. in Pharmacy (2006) and Ph.D. in Pharmaceutical Biosciences (2012) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

A workflow for evaluating and optimizing the designs of paediatric studiesRituximab PK and PD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarityRituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarityImeglimin Population Pharmacokinetics and Dose Adjustment Predictions for Renal Impairment in Japanese and Western Patients with Type 2 DiabetesPopulation Pharmacokinetic Modelling and Simulation of Imeglimin in Type 2 Diabetes Patients to Support Dose Recommendations to Patients with Renal ImpairmentCaplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura [2]Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD ModellingEffect of Plasma Exchange on the Pharmacokinetics and Pharmacodynamics of Caplacizumab, PS1487Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients with Acquired Thrombotic Thrombocytopenic Purpura, PB2249